Sanara MedTech (NASDAQ:SMTI – Get Free Report) and Neuronetics (NASDAQ:STIM – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Valuation & Earnings
This table compares Sanara MedTech and Neuronetics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sanara MedTech | $103.12 million | 3.13 | -$37.56 million | ($3.59) | -9.77 |
| Neuronetics | $149.16 million | 1.48 | -$39.00 million | ($0.44) | -6.59 |
Profitability
This table compares Sanara MedTech and Neuronetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sanara MedTech | -29.15% | 29.72% | 2.84% |
| Neuronetics | -19.62% | -125.11% | -22.15% |
Risk and Volatility
Sanara MedTech has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.
Insider and Institutional Ownership
8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 53.6% of Neuronetics shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 8.4% of Neuronetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and target prices for Sanara MedTech and Neuronetics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sanara MedTech | 1 | 4 | 0 | 0 | 1.80 |
| Neuronetics | 1 | 0 | 5 | 0 | 2.67 |
Sanara MedTech currently has a consensus price target of $35.00, suggesting a potential downside of 0.20%. Neuronetics has a consensus price target of $4.67, suggesting a potential upside of 60.92%. Given Neuronetics’ stronger consensus rating and higher possible upside, analysts plainly believe Neuronetics is more favorable than Sanara MedTech.
Summary
Neuronetics beats Sanara MedTech on 8 of the 13 factors compared between the two stocks.
About Sanara MedTech
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
About Neuronetics
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.
